Hiroshi Nagase
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiroshi Nagase has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Chie Seki
Pharmaceutical Research Laboratories, Toray Industries, Inc
1 shared publicationHideo Umeuchi
Pharmaceutical Research Laboratories, Toray Industries, Inc
1 shared publicationHiromasa Horikiri
Pharmaceutical Research Laboratories, Toray Industries, Inc
1 shared publicationJun Hayakawa
Pharmaceutical Research Laboratories, Toray Industries, Inc
1 shared publicationKen-Ichi Yoshizawa
Pharmaceutical Research Laboratories, Toray Industries, Inc
1 shared publicationKoji Kawai
Basic Resarch Laboratories, Toray Industrie's Inc
1 shared publication
Latest Publications
- 1 January 2004
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 52 (6) , 670-674
Syntheses of Potential Metabolites of a Potent .KAPPA.-Opioid Receptor Agonist, TRK-820
Chemical syntheses of three kinds of potential metabolites of TRK-820, a potent κ-opioid receptor agonist, were described. One of the potential metabolites 2, 17-N-dealkylated TRK-820, was synthesized starting from noroxycodone through 8 steps in 21% total yield. Glucuronidation of intermediate 10 and compound 1, the free base of TRK-820, was carried out stereoselectively to give 3-O-β-D-glucuronides 15 and 16 in good yields, respectively. Syntheses of potential conjugated metabolites 3 and 4 were accomplished through 10 steps and 2 steps in 11% and 43% total yields, respectively. Among the potential metabolites of TRK-820, compounds 2 and 4 were identified as metabolites in human hepatocytes. The results of pharmacological studies of compounds 2, 3, and 4 are described.
- 1 January 2004
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 52 (6) , 670-674
Syntheses of Potential Metabolites of a Potent .KAPPA.-Opioid Receptor Agonist, TRK-820
Chemical syntheses of three kinds of potential metabolites of TRK-820, a potent κ-opioid receptor agonist, were described. One of the potential metabolites 2, 17-N-dealkylated TRK-820, was synthesized starting from noroxycodone through 8 steps in 21% total yield. Glucuronidation of intermediate 10 and compound 1, the free base of TRK-820, was carried out stereoselectively to give 3-O-β-D-glucuronides 15 and 16 in good yields, respectively. Syntheses of potential conjugated metabolites 3 and 4 were accomplished through 10 steps and 2 steps in 11% and 43% total yields, respectively. Among the potential metabolites of TRK-820, compounds 2 and 4 were identified as metabolites in human hepatocytes. The results of pharmacological studies of compounds 2, 3, and 4 are described.
- 1 January 1989
- Published by The Society of Synthetic Organic Chemistry, Japan in Journal of Synthetic Organic Chemistry, Japan
- Vol. 47 (4) , 374-383
Abnormal reaction of 4,5-epoxydihydromorphinones and its application to the synthesis of opioid receptor antagonists.
Abnormal enolization reaction of naltrexone was found and the reactivity was applied to the syntheses of highly selective opioid receptor antagonists. Further, structure activity relationship of these antagonists was discussed.
- 1 January 1989
- Published by The Society of Synthetic Organic Chemistry, Japan in Journal of Synthetic Organic Chemistry, Japan
- Vol. 47 (4) , 374-383
Abnormal reaction of 4,5-epoxydihydromorphinones and its application to the synthesis of opioid receptor antagonists.
Abnormal enolization reaction of naltrexone was found and the reactivity was applied to the syntheses of highly selective opioid receptor antagonists. Further, structure activity relationship of these antagonists was discussed.